Particularly for pharmacy and medical students, Pharmacovigilance (PV) can seem like a labyrinth of acronyms, technical definitions, and regulatory jargon, but these terms are the foundation of drug safety monitoring globally, and knowing them well is crucial for both exams and real-world roles in clinical research, regulatory affairs, and the pharmaceutical industry.
Pharmacovigilance (PV) is the practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions.
Core Regulatory Terminologies You Must Know
- Absolute risk - Risk in a population of exposed persons; the probability of an event affecting members of a particular population (e.g., 1 in 1,000). Absolute risk can be measured over time (incidence) or at a given time (prevalence).
- Adverse event - Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment. Synonym: adverse experience.
- Association - Events associated in time but not necessarily linked as cause and effect.
- Attributable risk - Difference between the risk in an exposed population (absolute risk) and the risk in an unexposed population (reference risk). Also referred to as excess risk. Attributable risk is the result of an absolute comparison between outcome frequency measurements, such as incidence.
- Benefit - An estimated gain for an individual or a population. See also Effectiveness/Risk.
- Benefit - risk analysis - Examination of the favourable (beneficial) and unfavourable results of undertaking a specific course of action. While this phrase is still commonly used, the more logical pairings of benefit-harm and effectiveness-risk are slowly replacing it.
- Biological products - Medical products prepared from biological material of human, animal or microbiological origin (such as blood products, vaccines, insulin).
- Caveat document - The formal advisory warning accompanying data release from the WHO Database: it specifies the conditions and reservations applying to interpretations and use of the data.
- Dechallenge - The withdrawal of a drug from a patient, the point at which the continuity, reduction or disappearance of adverse effects may be observed.
- Phocomelia - Characteristic deformity caused by exposure to thalidomide in the womb, also very rarely occurring spontaneously. Meaning: limbs like a seal.
- Placebo - An inactive substance (often called a sugar pill) given to a group being studied to compare results with the effects of the active drug.
- Polypharmacy - The concomitant use of more than one drug, sometimes prescribed by different practitioners.
Why These Terms Matter
Understanding pharmacovigilance terminology helps you:
- Clear university and competitive exams
- Work confidently in PV, clinical research, and regulatory roles
- Interpret drug safety alerts and regulatory decisions
- Ensure patient safety in real-world practice
How do absolute risk and attributable risk differ in real-world drug safety assessment?
Can you think of a clinical scenario where this difference matters?
MBH/PS